Scarica l'app Stockscreener
712.87
0.97%
-7.01
Pre-mercato:
712.00
-0.87
-0.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$719.88
Aprire:
$719
Volume 24 ore:
795.15K
Relative Volume:
1.15
Capitalizzazione di mercato:
$74.74B
Reddito:
$14.92B
Utile/perdita netta:
$4.42B
Rapporto P/E:
17.37
EPS:
41.0422
Flusso di cassa netto:
$3.79B
1 W Prestazione:
+0.53%
1M Prestazione:
-5.64%
6M Prestazione:
+2.79%
1 anno Prestazione:
+24.77%
Intervallo 1D:
$710.06
$722.51
Intervallo di 1 settimana:
$701.99
$730.59
Portata 52W:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
712.87 | 75.47B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
450.41 | 114.99B | 12.34B | 4.34B | 3.71B | 16.87 |
ARGX
Argen X Se Adr
|
822.13 | 49.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.45 | 38.92B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.47 | 31.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-31 | Ripresa | Piper Sandler | Overweight |
| 2026-03-06 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2025-12-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Regeneron Pharma stock (US75886F1075): Active in competitive CD38 oncology landscape - AD HOC NEWS
Regeneron Pharmaceuticals stock (US75811P1003): Biotech leader in eye and oncology treatments - AD HOC NEWS
Regeneron Stock: What Management Just Said That the Market May Have Missed - TIKR.com
Regeneron Pharmaceuticals stock (US7739031091): Q1 earnings beat with $9.47 EPS - AD HOC NEWS
Bank of America Securities Sticks to Its Buy Rating for Regeneron (REGN) - The Globe and Mail
Freemont Management S.A. Takes $5.09 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by VIRGINIA RETIREMENT SYSTEMS ET Al - MarketBeat
Regeneron Pharma stock (US75886F1075): Biotech leader in eye and oncology treatments - AD HOC NEWS
Swiss Life Asset Management Ltd Has $8.31 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN) News, Articles, Events & Latest Updates - Stocktwits
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Regeneron Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
ETFs Investing in Regeneron Pharmaceuticals, Inc. Stocks - TradingView
Global Retinal Vein Occlusion Treatment Market to Exceed USD 5.5 - openPR.com
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Securian Asset Management Inc. - MarketBeat
Is Regeneron Pharmaceuticals (REGN) Among the Best Biotech Stocks to Invest In According to Billionaire Steve Cohen? - Insider Monkey
Peak Wealth Management LLC Invests $4.02 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN): Analyst Consensus And 22% Growth Potential - DirectorsTalk Interviews
Liquidity Mapping Around (REGN) Price Events - Stock Traders Daily
Regeneron's Portfolio Still Supports a Narrow Moat Despite Competitive Threats to Eylea - Morningstar
REGN SEC FilingsRegeneron Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
Osprey Private Wealth LLC Grows Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Otarmeni’s Accelerated FDA Approval - simplywall.st
Regeneron’s Otarmeni Win Links Gene Therapy Ambition With ESG Commitments - Yahoo Finance
Generali Asset Management SPA SGR Reduces Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
F m Investments LLC Has $17.61 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron drops despite Q1 beat, $3B share buyback program - MSN
Regeneron Pharma stock (US75886F1075): Biotech giant trades near $715 after modest gain on Friday - AD HOC NEWS
Follow The Sun - the-sun.com
Assessing Regeneron (REGN) After Recent Share Price Weakness And Strong Valuation Signals - simplywall.st
Regeneron (NASDAQ: REGN) reports $47.9M in 13F holdings - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Gene Therapy Briefs: Regeneron Wins FDA Approval for First Neurosensory Gene Therapy - Genetic Engineering and Biotechnology News
Will Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There. - The Motley Fool
Is This Biotech Stock a Buy After a Groundbreaking Approval? - AOL.com
Only 8 biotech companies made this global responsibility index — Regeneron did - Stock Titan
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Lmcg Investments LLC Grows Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by K.J. Harrison & Partners Inc - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Kiniksa hits 52-week high as Regeneron-partnered lead product drives Q1 beat - MSN
Bluebird Wealth Management LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
The top 12 companies hiring in biopharma now - BioSpace
Neurotrophic Keratitis Treatment Market Size Accelerating - openPR.com
Bayer to Acquire Perfuse for up to $2.45B, Seeing Ophthalmology Opportunity - Genetic Engineering and Biotechnology News
TD Cowen Initiates Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Announces Target Price $960 - 富途牛牛
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Swedbank AB - MarketBeat
Does Regeneron’s Gene Therapy Milestone and Buyback Shift the Bull Case For Regeneron Pharmaceuticals (REGN)? - simplywall.st
Insider Sell: Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN) - GuruFocus
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MSN
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.42%
0.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):